These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32648839)

  • 21. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
    Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
    Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane.
    Oh SJ; Jeltsch MM; Birkenhäger R; McCarthy JE; Weich HA; Christ B; Alitalo K; Wilting J
    Dev Biol; 1997 Aug; 188(1):96-109. PubMed ID: 9245515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
    Schomber T; Zumsteg A; Strittmatter K; Crnic I; Antoniadis H; Littlewood-Evans A; Wood J; Christofori G
    Mol Cancer Ther; 2009 Jan; 8(1):55-63. PubMed ID: 19139113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
    García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
    J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
    Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM
    Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CPT1A regulates breast cancer-associated lymphangiogenesis via VEGF signaling.
    Xiong Y; Liu Z; Zhao X; Ruan S; Zhang X; Wang S; Huang T
    Biomed Pharmacother; 2018 Oct; 106():1-7. PubMed ID: 29940537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.
    Eroğlu A; Ersöz C; Karasoy D; Sak S
    Adv Clin Exp Med; 2017; 26(2):245-249. PubMed ID: 28791841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
    Syväranta S; Helske S; Lappalainen J; Kupari M; Kovanen PT
    Atherosclerosis; 2012 Apr; 221(2):366-74. PubMed ID: 22281299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
    Rissanen TT; Markkanen JE; Gruchala M; Heikura T; Puranen A; Kettunen MI; Kholová I; Kauppinen RA; Achen MG; Stacker SA; Alitalo K; Ylä-Herttuala S
    Circ Res; 2003 May; 92(10):1098-106. PubMed ID: 12714562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
    Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils.
    de Paulis A; Prevete N; Fiorentino I; Rossi FW; Staibano S; Montuori N; Ragno P; Longobardi A; Liccardo B; Genovese A; Ribatti D; Walls AF; Marone G
    J Immunol; 2006 Nov; 177(10):7322-31. PubMed ID: 17082651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway.
    Choi JU; Chung SW; Al-Hilal TA; Alam F; Park J; Mahmud F; Jeong JH; Kim SY; Byun Y
    Biomaterials; 2017 Sep; 139():56-66. PubMed ID: 28586719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
    Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
    Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin.
    Enholm B; Karpanen T; Jeltsch M; Kubo H; Stenback F; Prevo R; Jackson DG; Yla-Herttuala S; Alitalo K
    Circ Res; 2001 Mar; 88(6):623-9. PubMed ID: 11282897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature.
    Costache MI; Ioana M; Iordache S; Ene D; Costache CA; Săftoiu A
    Rom J Intern Med; 2015; 53(3):199-208. PubMed ID: 26710495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
    He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
    J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.
    Visuri MT; Honkonen KM; Hartiala P; Tervala TV; Halonen PJ; Junkkari H; Knuutinen N; Ylä-Herttuala S; Alitalo KK; Saarikko AM
    Angiogenesis; 2015 Jul; 18(3):313-26. PubMed ID: 26018927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
    Yokoyama Y; Charnock-Jones DS; Licence D; Yanaihara A; Hastings JM; Holland CM; Emoto M; Sakamoto A; Sakamoto T; Maruyama H; Sato S; Mizunuma H; Smith SK
    Clin Cancer Res; 2003 Apr; 9(4):1361-9. PubMed ID: 12684405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
    Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
    Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Xiaotan Sanjie decoction inhibits angiogenesis in gastric cancer through Interleukin-8-linked regulation of the vascular endothelial growth factor pathway.
    Shi J; Lu Y; Wei P
    J Ethnopharmacol; 2016 Aug; 189():230-7. PubMed ID: 27224240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.